757
Participants
Start Date
March 31, 2006
Primary Completion Date
December 31, 2012
Study Completion Date
December 31, 2012
Rituximab plus immunosuppression
"Genetically engineered monoclonal antibody directed against the CD20 antigen on B cells and is known to deplete B cells when administered intravenously. Generally used in the treatment of non-Hodgkin's lymphoma~Standard immunosuppression is site-specific."
Placebo plus immunosuppression
"Placebo dosing: Adult Dosing (Subjects \>18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject \<\\=18 years): 375 mg/m\^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).~Standard immunosuppression is site-specific."
Children's Hospital of Philadelphia, Philadelphia
University of Maryland, Baltimore
University of Florida, Gainesville
University of Alabama, Pediatric Nephrology, Birmingham
University of Alabama, Birmingham
University of Illinois, Chicago
Northwestern University, Chicago
The Methodist Hospital, Houston
University of California, San Francisco, San Francisco
Legacy Transplant Services, Portland
Oregon Health Science University, Portland
Children's Hospital and Regional Medical Center, Seattle
Massachusetts General Hospital, Boston
Brigham and Women's Hospital, Boston
Children's Hospital Boston, Boston
Beth Israel Deaconess Medical Center, Boston
Saint Barnabas Medical Center, Livingston
Clinical Trials in Organ Transplantation
NETWORK
Cooperative Clinical Trials in Pediatric Transplantation (CCTPT)
UNKNOWN
National Institute of Allergy and Infectious Diseases (NIAID)
NIH